Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia / Mark H. Pollack en The Journal of Clinical Psychiatry, Año 2011 - Vol.72 - No. 7 (Julio)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 7 (Julio) . - pp. 892-897 Título : Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia : a randomized, double-blind, placebo controlled trial Tipo de documento: texto impreso Autores: Mark H. Pollack, Autor ; Elizabeth A. Hoge, Autor ; John J. Worthington, Autor Fecha de publicación: 2022 Artículo en la página: pp. 892-897 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Cuidado ambulatorio, Azabiciclo - Compuestos, Hipnóticos y sedantes, Piperazinas, Psicometría, Trastornos de iniciación y mantenimiento del sueño, Trastornos de estrés postraumático. Resumen: The development of novel strategies for the treatment of posttraumatic stress disorder (PTSD) represents a critical public health need. We present the first prospective, randomized, double-blind, placebo-controlled trial of a non-benzodiazepine hypnotic agent for the treatment of PTSD and associated insomnia. Link: ./index.php?lvl=notice_display&id=28019 [artículo] Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia : a randomized, double-blind, placebo controlled trial [texto impreso] / Mark H. Pollack, Autor ; Elizabeth A. Hoge, Autor ; John J. Worthington, Autor . - 2022 . - pp. 892-897. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 7 (Julio) . - pp. 892-897 Palabras clave: Cuidado ambulatorio, Azabiciclo - Compuestos, Hipnóticos y sedantes, Piperazinas, Psicometría, Trastornos de iniciación y mantenimiento del sueño, Trastornos de estrés postraumático. Resumen: The development of novel strategies for the treatment of posttraumatic stress disorder (PTSD) represents a critical public health need. We present the first prospective, randomized, double-blind, placebo-controlled trial of a non-benzodiazepine hypnotic agent for the treatment of PTSD and associated insomnia. Link: ./index.php?lvl=notice_display&id=28019

Placebo-controlled study of gabapentin treatment of panic disorder / Atul C. Pande en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Título : Placebo-controlled study of gabapentin treatment of panic disorder Tipo de documento: texto impreso Autores: Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor Fecha de publicación: 2023 Artículo en la página: pp. 467-471 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183 [artículo] Placebo-controlled study of gabapentin treatment of panic disorder [texto impreso] / Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor . - 2023 . - pp. 467-471. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Palabras clave: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183

Predictors of outcome following venlafaxine extended-release treatment of dsm-iv generalized anxiety disorder: a pooled analysis of short- and long-term studies / Mark H. Pollack en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 250-259 Título : Predictors of outcome following venlafaxine extended-release treatment of dsm-iv generalized anxiety disorder: a pooled analysis of short- and long-term studies Tipo de documento: texto impreso Autores: Mark H. Pollack, Autor ; Paolo Meoni, Autor ; Michael W. Otto, Autor Fecha de publicación: 2023 Artículo en la página: pp. 250-259 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos de ansiedad, Ciclohexanoles, Clorhidrato de venlafaxina Resumen: This pooled analysis evaluated potential predictive abilities of baseline demographic factors, psychiatric history, and DSM-IV diagnostic criteria for short- and long-term outcome after treatment with venlafaxine extended release (XR) or placebo in patients with generalized anxiety disorder (GAD). Link: ./index.php?lvl=notice_display&id=31021 [artículo] Predictors of outcome following venlafaxine extended-release treatment of dsm-iv generalized anxiety disorder: a pooled analysis of short- and long-term studies [texto impreso] / Mark H. Pollack, Autor ; Paolo Meoni, Autor ; Michael W. Otto, Autor . - 2023 . - pp. 250-259. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 250-259 Palabras clave: Trastornos de ansiedad, Ciclohexanoles, Clorhidrato de venlafaxina Resumen: This pooled analysis evaluated potential predictive abilities of baseline demographic factors, psychiatric history, and DSM-IV diagnostic criteria for short- and long-term outcome after treatment with venlafaxine extended release (XR) or placebo in patients with generalized anxiety disorder (GAD). Link: ./index.php?lvl=notice_display&id=31021

Tiagabine in adult patients with generalized anxiety disorder / Mark H. Pollack en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 3 (Junio) . - pp. 308-316 Título : Tiagabine in adult patients with generalized anxiety disorder : Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies Tipo de documento: texto impreso Autores: Mark H. Pollack, Autor ; Fang Xie, Autor ; Madhukar H. Trivedi, Autor Fecha de publicación: 2023 Artículo en la página: pp. 308-316 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Ansiolíticos, Trastornos de ansiedad, Ensayos Clínicos, Agonistas de GABA, Ácidos Nipecóticos. Resumen: The objective of these studies was to evaluate the efficacy and tolerability of tiagabine, a selective γ-aminobutyric acid reuptake inhibitor, in adult patients with generalized anxiety disorder (GAD). Patients with a diagnosis of GAD were enrolled in 1 of 3 randomized, placebo-controlled, 10-week studies. In each study, tiagabine was taken twice daily in divided doses-4, 8, or 12 mg/d in a fixed-dose study and 4-16 mg/d in two flexible-dose trials. Link: ./index.php?lvl=notice_display&id=30852 [artículo] Tiagabine in adult patients with generalized anxiety disorder : Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies [texto impreso] / Mark H. Pollack, Autor ; Fang Xie, Autor ; Madhukar H. Trivedi, Autor . - 2023 . - pp. 308-316. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 3 (Junio) . - pp. 308-316 Palabras clave: Ansiolíticos, Trastornos de ansiedad, Ensayos Clínicos, Agonistas de GABA, Ácidos Nipecóticos. Resumen: The objective of these studies was to evaluate the efficacy and tolerability of tiagabine, a selective γ-aminobutyric acid reuptake inhibitor, in adult patients with generalized anxiety disorder (GAD). Patients with a diagnosis of GAD were enrolled in 1 of 3 randomized, placebo-controlled, 10-week studies. In each study, tiagabine was taken twice daily in divided doses-4, 8, or 12 mg/d in a fixed-dose study and 4-16 mg/d in two flexible-dose trials. Link: ./index.php?lvl=notice_display&id=30852

---

1 (1 - 4 / 4)